Epcoritamab-Bysp 4 mg/0.8 mL, 48 mg/0.8 mL Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 4 mg/0.8 mL, 48 mg/0.8 mL
Reference Brands: EPKINLY (USA)
Category: Oncology Cancer Care
Epcoritamab (brand name Epkinly) is a bispecific monoclonal antibody that binds to both CD3 on T-cells and CD20 on B-cells, redirecting T-cells to kill malignant B-cells. It is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Administered subcutaneously, Epkinly provides an off-the-shelf immunotherapy alternative to CAR-T treatments. The medicine is jointly developed and marketed by AbbVie and Genmab.
Epcoritamab-Bysp — third party manufacturing & bulk supply
Epcoritamab-Bysp 4 mg/0.8 mL, 48 mg/0.8 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Epcoritamab-Bysp listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Epcoritamab-Bysp →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Epcoritamab-bysp is used for the treatment of adults with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. It works by engaging the patient’s T-cells to target and destroy malignant B-cells, offering a targeted immunotherapy approach for aggressive lymphomas.
Epcoritamab-bysp is made from Epcoritamab-bysp, a bispecific humanized monoclonal antibody that binds both CD3 on T-cells and CD20 on B-cells to promote immune-mediated destruction of cancerous B-cells.
The trade name of Epcoritamab-bysp is Epkinly.
Epcoritamab-bysp (Epkinly) is developed and manufactured by Genmab and AbbVie and marketed under approved regulatory pathways for B-cell lymphoma.
The generic name of Epcoritamab-bysp is Epcoritamab-bysp.
The brand name of Epcoritamab-bysp is Epkinly.
Epcoritamab-bysp is manufactured in the United States and Europe by Genmab and AbbVie under strict GMP conditions for oncology therapeutics.
Related Products
Fruquin 5 Mg (Fruquintinib)
Strength:
5 Mg
Form: Capsules
Reference Brands: Everest Bangladesh altd.
View Details
Vorinostat
Strength:
100 mg
Form: Capsules
Reference Brands: Zolinza (USA/EU), Vornat (India)
View Details
Panobinostat Lactate
Strength:
10 mg, 15 mg, 20 mg
Form: Capsules
Reference Brands: Farydak (USA/EU),
View Details
Gilteritinib
Strength:
40 mg
Form: Tablets
Reference Brands: Xospata (USA/India), LuciGil (Asia)
View DetailsQuick Response Guaranteed | Verified Suppliers
